LEPR and neoplasm: To this aim, we treated lean, obesity-resistant, overweight and obese mice with one injection per week of the active pegylated leptin receptor antagonist peptide (PEG-LPrA2) or with vehicle (control untreated) during 4 weeks, and assessed tumor volume at euthanasia.